[2] The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.

It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites.

Frovatriptan inhibits excessive dilation of arteries that supply blood to the head.

Frovatriptan has a terminal elimination half-life of approximately 26 hours, making it the longest within its class.

[4] Frovatriptan is available only by prescription in the United States and Canada, where a secondary New Drug Approval (sNDA) was filed in July 2006.